Thursday, May 1, 2008
For Lipitor King, It’s Deja Vu All Over Again
Four years ago, Roger Newton was the envy of the pharmaceutical industry when Pfizer bought his startup biotech Esperion Therapeutics and a handful of experimental compounds that raised good cholesterol for a cool $1.3 billion. Esperion CEO Roger Newton (AP Photo/Carlos Osorio) Little came of the venture for Pfizer, which shut the operation down last year amid [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment